Polymorphs of the mesylate salt of linaprazanglerate.

Stable crystalline mesylate salts of linaprazan glulate, formed via controlled crystallization, address solubility and stability issues, offering effective gastric acid suppression for prolonged periods in treating gastrointestinal diseases.

JP2024542115APending Publication Date: 2024-11-13CINCLUS PHARMA HLDG AB (PUBL)
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024526695
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-11-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Existing crystalline forms of linaprazan glulate exhibit low solubility, high hygroscopicity, and instability, limiting their effectiveness in pharmaceutical formulations for treating gastrointestinal inflammatory diseases.

Method used

Development of stable crystalline mesylate salts of linaprazan glulate, specifically Forms A and B, which possess higher solubility, low hygroscopicity, and improved chemical stability, achieved through controlled crystallization processes using solvents and antisolvents like 2-propanol, acetone, and MTBE.

Benefits of technology

The new crystalline forms maintain gastric pH above 4 for 24 hours, providing prolonged gastric acid suppression and improved bioavailability, suitable for treating conditions like erosive gastroesophageal reflux disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542115000012
    Figure 2024542115000012
  • Figure 2024542115000013
    Figure 2024542115000013
  • Figure 2024542115000014
    Figure 2024542115000014
Patent Text Reader

Abstract

The present invention relates to polymorphs of the mesylate salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazangrate), more particularly to Form A and Form B of the mesylate salt of linaprazangrate. The present invention also relates to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory or gastric acid related disorders, particularly erosive gastroesophageal reflux disease (eGERD).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Swedish Patent Application No. 2151355-1, filed November 5, 2021, the disclosure of which is incorporated herein by reference in its entirety.

[0002] The present invention relates to polymorphs of the mesylate salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazan glurate), more particularly to Form A and Form B of the mesylate salt of linaprazan glurate. The present invention also relates to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory or gastric acid related disorders, particularly erosive gastroesophageal reflux disease (eGERD). [Background technology]

[0003] The compound linaprazanurate (5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid, formerly known as X842) is disclosed in WO 2010 / 063876. Its structure is shown below. Linaprazanurate is a potassium ion-competitive acid blocker (P-CAB), which activates the gastric hydrogen potassium pump (H-KAP) in parietal cells. + / K + Linaprazanurate competitively inhibits the ATPase (ATPase) of the stomach. Linaprazanurate can therefore be used in the stomach to control the secretion of gastric acid.

[0004] [ka]

[0005] Linaprazanurate is a prodrug of linaprazan, which was disclosed in WO 99 / 55706 and previously studied in Phase I and Phase II trials. These studies showed that linaprazan was well tolerated, with a rapid onset of action and a maximum effect on the first dose. However, linaprazan was rapidly eliminated from the body, and the duration of acid suppression was too short. In contrast, linaprazanurate has a longer half-life in the body and shows complete control of gastric acid production for a longer period compared to linaprazan. A clinical Phase I trial showed that intragastric acidity above pH 4 could be maintained for 24 hours by administering a single dose of linaprazan. Linaprazanurate is therefore suitable for patients with severe erosive gastroesophageal reflux disease (eGERD).

[0006] For use in pharmaceutical formulations, it is desirable for active pharmaceutical ingredients (APIs) to be in a highly crystalline form. Non-crystalline (i.e., amorphous) materials may contain higher levels of residual solvents, which is undesirable. Also, due to their lower chemical and physical stability, amorphous materials may exhibit faster degradation and spontaneously form crystals with various degrees of crystallinity, as compared to crystalline materials. This can lead to unreproducible dissolution rates and difficulties in storing and handling the material.

[0007] Two crystalline forms of the free base of linaprazanurate are disclosed in CN10627915. Forms A and B of the free base were found to be anhydrates, and Form A was shown to have very low hygroscopicity. Although Form A has good physical and chemical stability and can be obtained with a high degree of crystallinity, it is practically insoluble in water at pH 6.8 and slightly soluble at pH 1. The low solubility limits the development of formulations with desirable properties. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] International Publication No. 2010 / 063876 [Patent Document 2] WO 99 / 55706 [Patent Document 3] CN10627915 [Non-patent literature]

[0009] [Non-Patent Document 1] R. Jenkins and R.L. Snyder, "Introduction to X-ray powder diffractometry", John Wiley & Sons, 1996 Summary of the Invention [Problem to be solved by the invention]

[0010] Therefore, there is a need for further crystalline forms of linaprazanurate with better properties than amorphous linaprazanurate and its previously disclosed crystalline forms.In particular, one object of the present invention is to provide a stable crystalline form of linaprazanurate that has good solubility, contains low levels of residual solvent, has high chemical stability and low hygroscopicity, and can be obtained with a high level of crystallinity. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows an X-ray powder diffractogram of Form A of the mesylate salt of linaprazanglerate obtained from a slurry in 2-propanol at RT ("Sample 1"). [Diagram 2] FIG. 1 shows an X-ray powder diffractogram of Form A of the mesylate salt of linaprazanglerate obtained from a slurry in acetone at RT ("Sample 2"). [Diagram 3]FIG. 1 shows the X-ray powder diffractogram of form B of the mesylate salt of linaprazanglerate crystallized from ethanol using MTBE as an anti-solvent. [Figure 4] FIG. 2 shows the thermogravimetric analysis (TGA) mass loss curve of Sample 1 of Form A. [Diagram 5] FIG. 2 shows the TGA mass loss curve of Sample 2 of Form A. [Figure 6] FIG. 2 shows the TGA mass loss curve of Form B. [Figure 7] FIG. 2 shows a differential scanning calorimetry (DSC) thermogram of Sample 1 of Form A. [Figure 8] FIG. 2 shows a differential scanning calorimetry (DSC) thermogram of Sample 2 of Form A. [Figure 9] FIG. 2 shows a differential scanning calorimetry (DSC) thermogram of Form B. [Figure 10] FIG. 1 shows the dynamic vapour sorption (DVS) mass change plot (A) and DVS isotherm plot (B) of Sample 1 of Form A. [Figure 11] FIG. 1 shows a dynamic vapour sorption (DVS) mass change plot (A) and a DVS isotherm plot (B) of Sample 2 of Form A. [Figure 12] FIG. 1 shows the DVS mass change plot (A) and DVS isotherm plot (B) of Form B. [Figure 13] FIG. 1 shows the solubility (μg / mL) of Form A in culture media simulating gastric and intestinal fluids (FaSSIF-V2, FeSSIF-V2 and FEDGAS). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] It has been discovered that under certain conditions, the mesylate salt of linaprazanurate can form stable crystalline forms (polymorphs). In addition to high crystallinity and high chemical stability, these polymorphs have significantly higher solubility than the free base forms A and B of linaprazanurate. Therefore, it is expected that this novel polymorph will be useful in pharmaceutical compositions of linaprazanurate. Thus, in a first aspect, the present invention relates to a crystalline mesylate salt of linaprazanurate.

[0013] In some embodiments, the present invention provides a crystalline mesylate salt of linaprazanglerate, which is stable at room temperature and 94% relative humidity (RH). Such crystalline mesylate salt can be stable under these conditions for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, or even longer.

[0014] In some embodiments, the crystalline mesylate salt is a hydrate, for example a non-stoichiometric hydrate.

[0015] In one embodiment, the crystalline hydrate is Form A. This highly crystalline form can be prepared, for example, from the mesylate salt of linaprazanglerate from a slurry in 2-propanol, acetone, MEK, acetonitrile, THF, or toluene; from acetone or THF, by evaporation; from DMF and by anti-solvent crystallization using ethyl acetate or MTBE as anti-solvent; or from 2-propanol, acetone, or THF by cooling. In one embodiment, Form A has an X-ray powder diffraction (XRPD) pattern obtained using CuKα1 radiation with at least two peaks at 2θ values ​​(°) selected from the list consisting of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.2. In some embodiments, Form A has an XRPD pattern obtained using CuKα1 radiation with at least peaks at 2θ values ​​(°) of 16.0±0.2 and 17.6±0.2, or 2θ values ​​(°) of 7.5±0.2 and 17.6±0.2. In some embodiments, Form A has an XRPD pattern obtained using CuKα1 radiation with at least four peaks at 2θ values ​​(°) selected from the list consisting of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.2. In some embodiments, Form A has an XRPD pattern obtained with CuKα1 radiation having at least peaks at 2θ values ​​(°) of 7.5±0.2, 9.1±0.2, 16.0±0.2, and 17.6±0.2. In some embodiments, Form A has an XRPD pattern obtained with CuKα1 radiation having at least six peaks at 2θ values ​​(°) selected from the list consisting of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.2.In some embodiments, Form A has an XRPD pattern obtained using CuKα1 radiation having at least peaks at 2θ values ​​(°) of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.2. In certain embodiments, the present invention relates to Form A having an XRPD pattern obtained using CuKα1 radiation substantially as shown in Figure 1 or Figure 2. In another particular embodiment, the present invention relates to Form A having an XRPD pattern obtained using CuKα1 radiation substantially as shown in Table 5 or Table 6.

[0016] In some embodiments, Form A has a DSC curve that includes an endotherm between about 175° C. and about 200° C. In certain embodiments, Form A has a DSC curve that includes an endotherm at approximately 190° C.

[0017] The water content of Form A can vary between about 0 and 1.7%, depending on the relative humidity. Water uptake increases almost linearly with increasing relative humidity. Thus, crystalline non-stoichiometric hydrates can be characterized as channel hydrates. Form A has been shown to incorporate 2-propanol and acetone into its channel structure. In some embodiments, Form A is stable at temperatures of 25° C. and up to 90% relative humidity.

[0018] In another embodiment, the crystalline hydrate is Form B. This form may be prepared by crystallization from ethanol using MTBE as an antisolvent. In one embodiment, Form B has an X-ray powder diffraction (XRPD) pattern obtained using CuKα1 radiation with at least two peaks at 2θ values ​​selected from the list consisting of 6.4±0.2, 7.0±0.2, 9.4±0.2, 14.6±0.2, 15.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.2. In some embodiments, Form B has an XRPD pattern obtained using CuKα1 radiation with at least peaks at 2θ values ​​(°) of 6.4±0.2 and 7.0±0.2. In some embodiments, Form B has an XRPD pattern obtained using CuKα1 radiation with at least four peaks at 2θ values ​​(°) selected from the list consisting of 6.4±0.2, 7.0±0.2, 9.4±0.2, 14.6±0.2, 15.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.2. In some embodiments, Form B has an XRPD pattern obtained using CuKα1 radiation with at least peaks at 2θ values ​​(°) of 6.4±0.2, 7.0±0.2, 9.4±0.2, and 15.6±0.2. In some embodiments, Form B has an XRPD pattern obtained with CuKα1 radiation having peaks at one or more of the following 2θ values ​​(°): 6.4±0.2, 7.0±0.2, 9.4±0.2, and 15.6±0.2, and 14.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.2. In some embodiments, Form B has an XRPD pattern obtained with CuKα1 radiation having peaks at one or more of the following 2θ values ​​(°): 6.4±0.2, 7.0±0.2, 9.4±0.2, 15.6±0.2, 18.2±0.2, 23.4±0.2, and 25.4±0.2.In some embodiments, Form B has an XRPD pattern obtained using CuKα1 radiation with at least peaks at 2θ values ​​(°) of 6.4±0.2, 7.0±0.2, 9.4±0.2, 14.6±0.2, 15.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.2. In some embodiments, Form B has an XRPD pattern obtained using CuKα1 radiation having peaks at one or more of the following 2θ values ​​(°): 6.4±0.2, 7.0±0.2, 9.4±0.2, 14.6±0.2, 15.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.2, and 19.0±0.2, 20.6±0.2, 21.3±0.2, 23.8±0.2, and 27.0±0.2. In certain embodiments, the present invention relates to Form B having an XRPD pattern obtained using CuKα1 radiation substantially as shown in FIG. 3. In another particular embodiment, the present invention relates to Form B having an XRPD pattern obtained using CuKα1 radiation substantially as shown in Table 5 or Table 7.

[0019] In some embodiments, Form B has a DSC curve containing a broad endotherm between about 100°C and about 130°C.

[0020] Between 0 and 90% RH, the water uptake of Form B increases almost linearly with increasing relative humidity. At 80% RH, the water content of Form B is about 3.4%. Thus, the crystalline non-stoichiometric hydrate is characterized as a channel hydrate. Form B has been shown to incorporate ethanol into its channel structure. In some embodiments, Form B is stable at temperatures of 25° C. up to 90% relative humidity.

[0021] In another aspect, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the crystalline mesylate salt of linaprazanurate as disclosed herein, together with one or more pharma- ceutically acceptable excipients.The excipients can include, for example, fillers, binders, surfactants, disintegrants, glidants and lubricants.In some embodiments, the crystalline mesylate salt of linaprazanurate is Form A.In some embodiments, the crystalline mesylate salt of linaprazanurate is Form B.

[0022] In some embodiments, the pharmaceutical composition comprises a crystalline mesylate salt of linaprazanurate, such as Form A or Form B, having a polymorphic purity of at least about 90%. In some embodiments, the polymorphic purity is at least about 95%. In some embodiments, the polymorphic purity is at least about 98%. For example, the polymorphic purity may be at least 98.5%, such as at least about 99%, such as at least about 99.5%, such as at least about 99.8%, or at least about 99.9%. In some embodiments, the pharmaceutical composition comprising the crystalline mesylate salt of linaprazanurate is substantially free of other forms of linaprazanurate. For example, in some embodiments, the pharmaceutical composition comprising Form A is substantially free of other forms of linaprazanurate, such as Form B of linaprazanurate. In some embodiments, Form A contains less than about 15% by weight of Form B of linaprazanurate or other polymorphs of linaprazanurate. For example, Form A contains less than about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1% or less by weight of linaprazangrate Form B or other polymorphs of linaprazangrate. In other embodiments, Form B contains less than about 15% by weight of linaprazangrate Form A or other polymorphs of linaprazangrate. For example, form B contains less than about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1% or less by weight of linaprazangrate form A or other polymorphs of linaprazangrate.

[0023] In some embodiments, the pharmaceutical composition may comprise between about 1% and about 100% by weight of the crystalline mesylate salt of linaprazanurate, such as between about 1% and about 50% by weight, or between about 1% and about 20% by weight. For example, the composition may comprise between about 1% and about 10% by weight, such as between about 5% and about 15% by weight, and between about 10% and about 20% by weight, or between about 1% and about 15% by weight, such as between about 1% and about 10% by weight, between about 5% and about 10% by weight, between about 10% and about 15% by weight, and between about 15% and about 20% by weight. In some embodiments, the composition comprises about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% by weight of the crystalline mesylate salt of linaprazanglerate.

[0024] In some embodiments, the composition comprises a unit dose of about 25 mg to about 150 mg of the crystalline mesylate salt of linaprazanglerate. For example, the composition can comprise between about 25 mg to about 50 mg, between about 50 mg to about 75 mg, between about 75 mg to about 100 mg, between about 100 mg to about 125 mg, or between about 125 mg to about 150 mg. In some embodiments, the composition comprises about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, or about 150 mg of the crystalline mesylate salt of linaprazanglerate. The daily dose may be administered as a single dose or divided into two, three or more unit doses.

[0025] In some embodiments, the pharmaceutical composition comprises a surfactant. The surfactant may be a cationic surfactant, an anionic surfactant, or a non-ionic surfactant. Examples of cationic surfactants include, but are not limited to, cetyltrimethylammonium bromide (cetrimonium bromide) and cetylpyridinium chloride. Examples of anionic surfactants include, but are not limited to, sodium dodecyl sulfate (sodium lauryl sulfate) and ammonium dodecyl sulfate (ammonium lauryl sulfate). Examples of non-ionic surfactants include, but are not limited to, glycerol monooleate, glycerol monostearate, polyoxyl castor oil (Cremophor EL), poloxamer (e.g., poloxamer 407 or poloxamer 188), polysorbate 80, and sorbitan esters (Tween).

[0026] In some embodiments, the pharmaceutical composition comprises a filler. Examples of suitable fillers include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose (such as lactose monohydrate), sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, dry starch, hydrolyzed starch, and pregelatinized starch.

[0027] In some embodiments, the pharmaceutical composition comprises a binder. Examples of suitable binders include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (such as sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, wax, natural and synthetic gums (such as gum acacia and gum tragacanth), sodium alginate, cellulose derivatives (such as hydroxypropylmethylcellulose (or hypromellose), hydroxypropylcellulose and ethylcellulose) and synthetic polymers (such as acrylic and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid copolymers and polyvinylpyrrolidone (povidone)).

[0028] In some embodiments, the pharmaceutical composition comprises a disintegrant.Suitable examples of disintegrants include, but are not limited to, dry starch, modified starch (such as (partially) pregelatinized starch, sodium starch glycolate and sodium carboxymethyl starch), alginic acid, cellulose derivatives (such as sodium carboxymethylcellulose, hydroxypropylcellulose and low-substituted hydroxypropylcellulose (L-HPC)) and crosslinked polymers (such as carmellose, croscarmellose sodium, carmellose calcium and crosslinked PVP (crospovidone)).

[0029] In some embodiments, the pharmaceutical composition comprises a glidant or lubricant. Examples of suitable glidants and lubricants include, but are not limited to, talc, magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, glyceryl behenate, colloidal anhydrous silica, aqueous silicon dioxide, synthetic magnesium silicate, finely divided silicon oxide, starch, sodium lauryl sulfate, boric acid, magnesium oxide, wax (such as carnauba wax), hydrogenated oil, polyethylene glycol, sodium benzoate, polyethylene glycol, and mineral oil.

[0030] In general, pharmaceutical compositions can be prepared in conventional forms using conventional excipients. In some embodiments, the ingredients of the formulation are mixed into a homogenous mixture and then formulated as a tablet or capsule. The homogenous mixture of ingredients can be compressed into tablets using conventional techniques, such as a rotary tablet press. The mixture of ingredients can be granulated. For example, the mixture of ingredients can be moistened by adding a liquid, such as water and / or a suitable organic solvent (e.g., ethanol or isopropanol), and then granulated and dried. Alternatively, granules can be prepared by dry granulation, such as by roller compaction. The resulting granules can be compressed into tablets using conventional techniques. Capsules can contain a powder mixture of ingredients or small multiparticulates of ingredients (such as granules, extruded pellets, or minitablets). If desired, any of the above tablets, capsules, granules, extruded pellets, and minitablets can be coated with one or more coating layers. Such coating layers may be applied by methods known in the art, such as by film coating, including perforated pans and fluidized beds, hi some embodiments, the formulation is in the form of a tablet.

[0031] Following absorption into the bloodstream, linaprazanurate is rapidly metabolized to the active metabolite, linaprazan. Plasma concentrations of linaprazanurate are very low and difficult to measure, but plasma concentrations of linaprazan may be measured instead. Phase I studies have demonstrated that certain doses of linaprazanurate should be able to maintain an intragastric pH above pH 4 for 24 hours after administration. This requires a minimum plasma concentration (C) of linaprazan of at least about 240 nmol / L after 22 hours. min) is estimated to be necessary. At such doses, once-daily oral administration of the formulation would be sufficient. Thus, in some embodiments, a single unit dose of the pharmaceutical composition of linaprazan provides a C of linaprazan in a human of at least about 240 nmol / L 22 hours after oral administration of the pharmaceutical composition to said human. min In another embodiment, daily administration of two unit doses of the pharmaceutical composition of linaprazan results in a C of linaprazan in a human of at least about 240 nmol / L 10 hours after oral administration of the last unit dose of the pharmaceutical composition to the human. min This results in:

[0032] In one aspect, the present invention relates to a crystalline form of the mesylate salt of linaprazanglerate disclosed herein for use in therapy.

[0033] The crystalline form of the mesylate salt of linaprazanurate disclosed herein may be used in the treatment or prevention of diseases or conditions in which inhibition of gastric acid secretion is necessary or desirable, such as eradication of H. pylori. Examples of such diseases and conditions include gastritis, gastroesophageal reflux disease (GERD), erosive gastroesophageal reflux disease (eGERD), H. pylori infection, Zollinger-Ellison syndrome, gastrointestinal inflammatory diseases and gastric acid-related diseases such as peptic ulcer disease (including gastric and duodenal ulcers), bleeding gastric ulcers, symptoms of gastroesophageal reflux disease (including heartburn, regurgitation and nausea), gastrinoma and acute upper gastrointestinal bleeding.

[0034] Thus, in one aspect, the present invention relates to a method for treating or preventing gastrointestinal inflammatory disease or gastric acid-related disease in a subject in need thereof, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of the mesylate salt of linaprazanurate as disclosed herein.In some embodiments, the crystalline form of the mesylate salt of linaprazanurate is Form A.In some embodiments, the crystalline form of the mesylate salt of linaprazanurate is Form B.

[0035] In some embodiments, the treatment for GERD is an on-demand treatment for GERD.

[0036] In another aspect, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the crystalline mesylate salt of linaprazanglerate disclosed herein for use in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid-related diseases.

[0037] As used herein, the term "polymorph" refers to crystals of the same molecule that have different physical properties as a result of the order of the molecules in the crystal lattice. Polymorphs of a single compound have one or more different chemical, physical, mechanical, electrical, thermodynamic, and / or biological properties. The differences in physical properties exhibited by polymorphs may affect pharmaceutical parameters such as storage stability, compressibility, density (important in the manufacture of compositions and products), dissolution rate (an important factor in determining bioavailability), solubility, melting point, chemical stability, physical stability, powder flowability, moisture sorption, compaction, and particle morphology. Differences in stability may result from changes in chemical reactivity (e.g., different oxidation, such that a dosage form consisting of one polymorph discolors faster than one consisting of another polymorph), or mechanical changes (e.g., crystals change on storage such that a kinetically favored polymorph transforms into a thermodynamically more stable polymorph), or both (e.g., one polymorph is more hygroscopic than the other). As a result of differences in solubility / dissolution, some transitions affect efficacy and / or toxicity. Additionally, the physical properties of the crystals may be important in processing, for example, one polymorph may be more likely to form solvates or it may be difficult to filter and wash out impurities (i.e., particle shape and particle size distribution may differ between one polymorph and another). "Polymorph" does not include amorphous forms of a compound.

[0038] As used herein, the term "amorphous" refers to a non-crystalline form of a compound, which may be a solid state form of the compound or a solubilized form of the compound. For example, "amorphous" refers to a compound that does not have a regularly repeating arrangement of molecules or external face planes.

[0039] As used herein, the term "polymorphic purity" when used in reference to a composition comprising a polymorph of linaprazanurate refers to the ratio of one particular polymorph to another polymorph or amorphous form of linaprazanurate in the referenced composition. For example, a composition comprising Form A having a polymorphic purity of 90% would contain 90 parts by weight of Form A and 10 parts by weight of other crystalline and / or amorphous forms of linaprazanurate.

[0040] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of linaprazanurate that will, after administration to a subject, relieve to some extent one or more symptoms of the disease or condition being treated. The result includes reduction and / or alleviation of the signs, symptoms, or causes of the disease, or other desired changes in a biological system. For example, an "effective amount" for therapeutic use is the amount of linaprazanurate required to cause a clinically significant reduction in disease symptoms. The appropriate "effective" amount in any individual case can be determined using any suitable technique, such as a dose escalation study.

[0041] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of a disease or disorder described herein, or one or more symptoms thereof, or inhibiting the progression of a disease or disorder described herein, or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible person prior to the onset of symptoms (e.g., taking into account a history of symptoms and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, e.g., to prevent or delay the recurrence of symptoms.

[0042] As used herein, the term "pharmaceutical acceptable" refers to those compounds, substances, compositions and / or dosage forms that are suitable for human pharmaceutical use and are generally safe, non-toxic and not biologically or otherwise undesirable.

[0043] As used herein, a compound or composition is "substantially free" of one or more other components if the compound or composition does not contain a significant amount of the other components. Such components may include impurities such as starting materials, residual solvents, or other impurities that may result from the preparation and / or isolation of the compounds and compositions provided herein. In some embodiments, the polymorphic forms provided herein are substantially free of other polymorphic forms. In some embodiments, the polymorphic forms provided herein are "substantially free" of impurities. The purity of a particular polymorph is preferably greater than about 90% (w / w), such as greater than about 95% (w / w), such as greater than about 97% (w / w), or even greater than about 99% (w / w). In some embodiments, the purity of a particular polymorph is greater than 99.5% (w / w), or even greater than 99.9% (w / w). In some embodiments, the amount of a particular polymorphic impurity is less than about 1% (w / w), such as less than about 0.5% (w / w), or less than about 0.1% (w / w). The total amount of impurities is measured, for example, by high performance liquid chromatography (HPLC) methods.

[0044] In some embodiments, a particular polymorph of linaprazanurate is "substantially free" of other polymorphs when it constitutes at least about 95% by weight of the linaprazanurate present. In some embodiments, a particular polymorph of linaprazanurate is "substantially free" of other polymorphs when it constitutes at least about 97%, about 98%, about 99%, or about 99.5% by weight of the linaprazanurate present.

[0045] As used herein, a compound is "substantially present" as a given polymorph when at least about 50% by weight of the compound is in the form of that polymorph, such as when at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, or at least about 90% by weight of the compound is in the form of that polymorph. In some embodiments, at least about 95% by weight of the compound is in the form of that polymorph, such as at least about 96% by weight, such as at least about 97% by weight, such as at least about 98% by weight, such as at least about 99% by weight, or at least about 99.5% by weight.

[0046] As used herein, the term "stable" means that the polymorph does not show a change in one or more polymorphic forms (e.g., an increase or decrease in a particular form), appearance, pH, percent impurities, activity (measured by in vitro assay), or osmolality over time. In some embodiments, the polymorphs provided herein are stable for at least 1, 2, 3, or 4 weeks. For example, the polymorph does not show a change in one or more polymorphic forms (e.g., an increase or decrease in a particular form), appearance, pH, percent impurities, activity (measured by in vitro assay), or osmolality over at least 1, 2, 3, or 4 weeks. In some embodiments, the polymorphs provided herein are stable for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. For example, the polymorph does not exhibit a change in one or more polymorphic forms (e.g., an increase or decrease in a particular form), appearance, pH, percent impurities, activity (as measured by in vitro assays), or osmolality over a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In the above, the phrase "exhibits no change" refers to less than a 5% (e.g., less than 4%, less than 3%, less than 2%, less than 1%) change measured for any of the parameters over that period of time.

[0047] The crystallinity of the polymorph of the mesylate salt of linaprazanurate can be measured, for example, by X-ray powder diffraction (XRPD) or by differential scanning calorimetry (DSC). When referring to crystalline compounds herein, the crystallinity is preferably greater than about 70%, such as greater than about 80%, particularly greater than about 90%, and more particularly greater than about 95%. In some embodiments, the crystallinity is greater than about 98%. In some embodiments, the crystallinity is greater than about 99%. % crystallinity refers to the mass percent of the total sample mass that is crystalline.

[0048] As used herein, the term "about" refers to a value or parameter herein, including (and describing) embodiments directed to that value or parameter itself. For example, a statement referring to "about 20" includes the statement "20." Numeric ranges include the numbers that define the range. Generally speaking, the term "about" refers to the stated value of a variable, and all values ​​of the variable that are within experimental error of the stated value (e.g., within a 95% confidence interval about the mean) or within 10% of the stated value, whichever is greater.

[0049] The invention will now be illustrated by the following examples, which are not intended to limit the invention in any way. All cited documents and references mentioned herein are incorporated by reference in their entirety.

[0050] Abbreviation DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide EtOAc Ethyl acetate EtOH Ethanol MEK Methyl ethyl ketone MTBE Methyl tert-butyl ether MeOH Methanol RH Relative Humidity THF Tetrahydrofuran

[0051] Experimental Method General method 1 H-NMR spectra were recorded on a Bruker 400 MHz instrument at 25 °C. Deuterated solvent used: DMSO-d6 (δ H The residual protic solvent in the sample was determined based on 2.50 ppm.

[0052] Analytical HPLC-MS was performed using an Agilent 1100 Series Liquid Chromatography / Mass Selective Detector (MSD) (single quadrupole) equipped with an electrospray interface and a UV diode array detector. The analysis was performed using an ACE3C8 (3.0 x 50 mm) column with a gradient of acetonitrile in 0.1% aqueous TFA at a flow rate of 1 mL / min over 3 min.

[0053] For the solubility study, HPLC was performed using an Agilent 1100 series liquid chromatography system equipped with a DAD spectrometer. The analysis was performed using a Waters XBridge BEH C18 column (4.6×100 mm, 2.5 μm) at 30° C. Mobile phase: A=0.1% formic acid in water, B=0.1% formic acid in acetonitrile. Flow rate 0.8 mL / min. The mobile phase program is as follows:

[0054] [Table 1]

[0055] X-ray powder diffraction (XRPD) analysis The analyses were performed on a PanAlytical X'Pert Pro diffractometer equipped with a Cu anode (45 kV, 40 mA), a Kα-1 Johansson monochromator (1.540598 Å) and a Pixcel detector. The 2θ range was 2-35° using a step size of 0.013° and a scan speed of 0.10° / s ("6 min scan") or 0.03° / s ("20 min scan"). Slow spinning sample holders were used. Samples were smeared onto Si zero background wafers to obtain a flat powder-like surface. Measurements were performed using a programmable incident divergence slit.

[0056] It is known in the art that X-ray powder diffraction patterns are obtained with one or more measurement errors depending on the measurement conditions (such as the device, sample preparation, or machine used). In particular, it is generally known that the intensity of an XRPD pattern can increase or decrease depending on the measurement conditions and sample preparation. For example, a person skilled in the art of XRPD will understand that the relative intensity of peaks can vary depending on the orientation of the sample under test and the type and settings of the instrument used. A person skilled in the art will also understand that the position of reflections can be influenced by the exact height at which the sample is located in the diffractometer and the zero calibration of the diffractometer. The surface planarity of the sample may also have a small effect. Therefore, a person skilled in the art will understand that the diffraction patterns presented herein should not be taken as absolute, and any crystalline form that results in a powder diffraction pattern that is substantially identical to the powder diffraction pattern disclosed herein falls within the scope of the present disclosure (for further information, see R. Jenkins and RLSnyder, "Introduction to X-ray powder diffractometry", John Wiley & Sons, 1996).

[0057] Thermogravimetric analysis (TGA) The analysis was carried out on a PerkinElmer TGA7 instrument.

[0058] Method 1: A few mg of sample were gently placed into an open Pt pan and mass analyzed from 25 to 140 °C using a continuous scan speed of 10 °C / min, followed by an isothermal step at 140 °C for 60 min (which was manually terminated if the drying process was completed before 60 min) with a flow of dry nitrogen gas (20 mL / min) to ensure an inert atmosphere.

[0059] Method 2: A few milligrams of sample were gently placed in an open Pt pan and mass analyzed from 25 to 30 °C using a continuous scan speed of 10 °C / min, followed by an isothermal step of 15 min at 30 °C with a flow of dry nitrogen gas (20 mL / min) to ensure an inert atmosphere. The temperature was then increased from 30 to 110 °C using a continuous scan speed of 10 °C / min, and finally ended with an isothermal step of 44 min at 110 °C (the analysis was manually terminated).

[0060] Differential scanning calorimetry (DSC) The analyses were carried out on a Netzsch DSC204F1 instrument.

[0061] A few mg of sample was gently placed into an Al pan and weighed. A lid with a small pre-drilled hole was fitted to the pan and crimped. A conventional DSC was used with a heating rate of 10°C / min. The minimum temperature (onset) was 0°C and the maximum temperature was 250°C.

[0062] Dynamic vapor sorption (DVS) Analyses were performed on an SMS DVS-1 instrument.

[0063] Method 1: A few mg of material were placed in an Al pan and exposed to stepwise RH changes during two identical successive cycles according to 0-10-20-30-40-50-60-70-80-90-80-70-60-50-40-30-20-10-0% RH using open loop mode. The experiments were carried out at 25° C. using a gas flow rate of 200 mL / min. For all steps, except the first step, which was set for a fixed time of 12 h, the applied dm / dt criterion was 0.001 wt % / min in a window of 5 min with a maximum allowable time of 360 min and a minimum allowable time of 10 min.

[0064] Method 2: A few mg of material were placed in an Al pan and exposed to stepwise RH changes during two identical successive cycles according to 0-10-20-30-40-50-60-70-80-90-80-70-60-50-40-30-20-10-0% RH using open loop mode. Experiments were performed at 25° C. using a gas flow rate of 200 mL / min. For all steps, the applied dm / dt criterion was 0.001 wt % / min in a window of 5 min with a maximum allowable time of 360 min and a minimum allowable time of 10 min.

[0065] Method 3: A few mg of material were placed in an Al pan and exposed to stepwise RH changes during two identical successive cycles according to 0-10-20-30-40-50-60-70-80-90-80-70-60-50-40-30-20-10-0% RH using open loop mode. The experiments were carried out at 25° C. using a gas flow rate of 200 mL / min. For all steps, except the first step, which was set for a fixed time of 6 h, the applied dm / dt criterion was 0.001 wt % / min in a window of 5 min with a maximum allowable time of 360 min and a minimum allowable time of 10 min. EXAMPLES

[0066] Example 1 <Preparation of linaprazanglerate mesylate salt> Linaprazanglerate (0.500 g, 1.04 mmol) was suspended in 2-propanol (25 mL) at 22° C. and the suspension was stirred. Methylsulfonic acid (99.0 mg, 1.03 mmol) was added and the resulting mixture was heated to 80° C. to completely dissolve all solids. The solution was then concentrated under reduced pressure. Yield: 103% (0.615 g, colorless powder), 100% pure by LCMS. 1H NMR (400 MHz, DMSO-d6): δ 13.70 (s, 1H), 12.07 (s, 1H), 8.92 (t, J = 5.6 Hz, 1H), 8.35 (d, J = 1.3 Hz, 1H), 7.51-6.98 (m, 4H), 6.08 (s, 1H), 4.42 (d, J = 3.9 Hz, 2H), 4.21 (t, J = 5.7 Hz, 2H), 3.58 (q, J = 5.7 Hz, 2H), 2.44-2.21 (m, 15H), 1.74 (p, J = 7.4 Hz, 2H). MS: (ESI+) m / z 481 (M+H).

[0067] Example 2 <Polymorph screening> A polymorph screening was performed on the mesylate salt of linaprazanurate to determine the solubility, polymorphism and thermodynamic stability.

[0068] X-ray powder diffraction (XRPD), thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC) showed that the drug substance used for screening was completely amorphous. Prior to the crystallization experiments, the solubility of the drug substance was measured in >20 solvents and solvent mixtures.

[0069] <Slurry experiment>: Slurry experiments were performed in a variety of solvents. Approximately 30-120 mg of drug substance was slurried in a number of different pure and binary solvents at room temperature and at 40° C. All solvents were dried by adding molecular sieves before preparing the slurries. Unless otherwise stated, solid phases were isolated after 13 days and analyzed by XRPD. Crystalline solid forms were obtained in the experiments shown in Table 1.

[0070] [Table 2]

[0071] <Evaporation experiment>: The experiments were carried out in solvents in which the mesylate salt of linaprazanurate was found to have sufficiently high solubility. All solvents were dried by adding molecular sieves before preparing the solutions. Approximately 10-25 mg of drug substance was dissolved and left to evaporate slowly in the vial or directly on the XRPD zero background plate. The experiments were carried out at room temperature, 40°C, or 45°C and ambient relative humidity. Crystalline solid forms were obtained in the experiments shown in Table 2.

[0072] [Table 3]

[0073] <Anti-solvent crystallization>: Crystallization was performed from certain solvents in which the mesylate salt of linaprazanurate was found to have high solubility, along with certain antisolvents in which the mesylate salt of linaprazanurate was found to be almost insoluble. All solvents were dried by adding molecular sieves before the experiments were performed. The drug substance was dissolved in solvent 1 and solvent 2, and then added in 0.2 mL portions. Samples were stored at RT (room temperature) unless otherwise stated. Crystalline solid forms were obtained in the experiments shown in Table 3.

[0074] [Table 4]

[0075] <Cooling Experiment>: Cooling experiments were performed in selected solvents in which solid material formed in the corresponding slurry experiments. Approximately 25 mg of drug substance was first dissolved or partially dissolved at room temperature, followed by precipitation of the solid material. After precipitation, the clear supernatant was transferred to a new vial and heated to approximately 45° C. to completely dissolve the drug substance. The vial was then placed in a refrigerator at 5° C. A crystalline solid form was obtained in the experiment shown in Table 4.

[0076] [Table 5]

[0077] The XRPD peaks of Form A ("Sample 1") obtained from a slurry in 2-propanol at RT (room temperature) are set forth below in Table 5. The diffractogram of Form A Sample 1 is shown in FIG.

[0078] [Table 6A]

[0079] [Table 6B]

[0080] The XRPD peaks of Form A ("Sample 2") obtained from a slurry in acetone at RT are set forth below in Table 6. The diffractogram of Form A Sample 2 is shown in FIG.

[0081] [Table 7A]

[0082] [Table 7B]

[0083] The XRPD peaks of Form B crystallized from ethanol using MTBE as the anti-solvent are listed below in Table 7. The diffractogram of Form B is shown in FIG.

[0084] [Table 8]

[0085] The pyridine solvate obtained in the pyridine slurry experiment was a highly crystalline solid form, but was not considered pharma- ceutically viable. TGA experiments confirmed that this form contained approximately 2 moles of pyridine per mole of the mesylate salt of linaprazanglerate.

[0086] Example 3 <Thermogravimetric analysis> Form A was analyzed using Method 1. Form A Samples 1 and 2 exhibited mass losses of 1.2% and 1.1%, respectively, upon heating from 25 to 140° C. Form A was concluded to be a non-stoichiometric solvate / hydrate (the 1:1 propanol solvate would have had a 9% mass loss and the 1:1 hydrate would have had a 3% mass loss). The TGA mass loss curves of Form A Samples 1 and 2 are shown in FIG. 4 and FIG. 5, respectively.

[0087] After the TGA experiment, XRPD analysis of Form A sample 1 confirmed that this form remained (diffractogram not shown).

[0088] Form B was analyzed using Method 2. A sample (obtained by crystallization from ethanol using MTBE as antisolvent) was dried isothermally at 30° C. to release loosely bound water, and then dried isothermally at 110° C. to release solvent from possible solvates. When loosely bound solvent was excluded, the mass loss of Form B was calculated to be 2.9%. The mass loss is due to the release of water. Form B was concluded to be a non-stoichiometric solvate (the 1:1 ethanol solvate would have had a mass loss of 7.4% and the 1:1 MTBE solvate would have had a mass loss of 13.3%). The TGA mass loss curve of Form B is shown in FIG. 6.

[0089] Example 4 <Differential scanning calorimetry (DSC) analysis> Sample 1 of Form A (obtained from a slurry in 2-propanol) showed a single endothermic event at approximately 190° C. (onset), which can be attributed to crystalline melting. Sample 2 of Form A (obtained from a slurry in acetone) was lightly crushed to remove agglomerates and then tightly packed into a DSC crucible. The sample showed a broad endotherm at approximately 180° C. (onset), suggesting two overlapping events in the melting temperature region. The DSC thermograms of Samples 1 and 2 of Form A are shown in FIG. 7 and FIG. 8, respectively.

[0090] The sample of Form B showed only one broad endothermic event at approximately 120° C., which is interpreted as simultaneous solvent release and melting. The DSC thermogram of Form B is shown in FIG.

[0091] Example 5 <Dynamic Vapor Sorption (DVS) Analysis> The hygroscopicity of Form A sample 1 (obtained from a slurry in 2-propanol) was investigated using method 1. The mass change plot shows two simultaneous events: linear water uptake and solvent (2-propanol) release with increasing relative humidity. Linear sorption and desorption imply that the crystal structure contains channels or voids through which water can be absorbed or released, depending on the change in humidity in the surrounding atmosphere. It is possible that small solvent molecules (such as 2-propanol) occupy these channels or voids. In the DVS experiment, the solvent molecules are first released by drying at 0% RH and then replaced by water molecules as the RH is increased. The mass change plot and sorption isotherm plot are shown in Figure 10A and Figure 10B, respectively.

[0092] For sample 2 of Form A (obtained from a slurry in acetone), the TGA dried sample was examined using method 2. The two cycles of mass change curves are not identical. The first cycle may be affected by the TGA drying procedure preceding the DVS experiment. It is possible that drying at elevated temperature disrupted some of the crystal structure. The increase in sorption in the first cycle can then be interpreted as a combination of "pure" moisture sorption and crystal structure order as water activity increases. In the second cycle, "pure" moisture absorption and desorption are recorded. Linear sorption and desorption means that the crystal structure contains channels or voids through which moisture can be absorbed or released in response to changes in humidity in the surrounding atmosphere. The mass change plot and sorption isotherm plot for sample 2 of Form A are shown in Figure 11A and Figure 11B, respectively.

[0093] After DVS analysis, XRPD analysis of sample 2 of Form A confirmed that this form remained (diffractogram not shown).

[0094] Method 3 was used to investigate the hygroscopicity of Form B. As shown in the mass change plot and sorption isotherm plot (see FIG. 12A and FIG. 12B, respectively), the first and second cycles are clearly different. In the first cycle, as the water activity increases, the solvent is replaced by water. Since the solid material was obtained from anti-solvent experiments with MTBE and ethanol, the trapped solvent is most likely ethanol. In the second cycle, "pure" water sorption appears. The linear water absorption and desorption in the second cycle indicates that Form B is a channel hydrate.

[0095] Example 6 <Solubility research> <Solubility of Form A in culture media simulating gastric and intestinal fluids> The solubility of Form A in mid-stage fed-state simulated gastric fluid (FEDGAS), fasted-state simulated intestinal fluid version 2 (FaSSIF-2), and fed-state simulated intestinal fluid version 2 (FeSSIF-2) was studied.

[0096] Preparation of buffer solutions <fassif-v2>: To 90 mL of MilliQ water, 139 mg of NaOH, 222 mg of maleic acid, and 401 mg of NaCl were added and the mixture was stirred until completely dissolved. The pH was adjusted to 6.5 with 1 M HCl and 1 M NaOH and made up to 100 mL with MilliQ water. 179 mg of FaSSIF-V2 (Biorelevant, V2FAS-1020-A batch) was mixed with 100 mL of the prepared buffer, stirred until completely dissolved, and equilibrated at RT for 1 h before use.

[0097] <fessif-v2>: To 90 mL of MilliQ water, 327 mg of NaOH, 639 mg of maleic acid and 733 mg of NaCl were added, and the resulting mixture was stirred until completely dissolved. The pH was adjusted to 5.8 with 1 M HCl and 1 M NaOH, and made up to 100 mL with MilliQ water. 976 mg of FeSSIF-V2 (Biorelevant, batch V2FES-1020-A) was mixed with 100 mL of the prepared buffer solution, stirred until completely dissolved, and equilibrated at RT for 1 hour before use.

[0098] <FEDGAS (intermediate stage, pH 4.5)>: 3.68 g of FEDGAS buffer concentrate (Biorelevant, batch FEDBUF45-0122-A), 73.1 g of MilliQ water, and 15.3 g of FEDGAS gel (Biorelevant, batch FEDGAS-0322-A) were thoroughly mixed. The medium was stored at 37 °C before use.

[0099] Sample preparation, analysis and results Saturated solutions were prepared in 4 mL vials by adding a fixed mass (excess) of Form A to 2 mL of each of the different buffer solutions. Each experiment was repeated twice. These solutions were stirred using a magnetic stirrer at 37 °C for 24 hours. Samples were taken after 1, 3, 6, and 24 hours. At each sample collection point, 200 μL of the sample solution was filtered using a 0.2 μg PP syringe-less filter. The filtered sample solution was diluted 2-fold or 5-fold with DMA and then analyzed by HPLC-UV to measure the concentration of linaprazan gulonate. The concentration was calculated from a calibration curve based on seven calibration standards (stock solutions of 100 and 250 μg / ml and their serial dilutions).

[0100] The solubility of Form A in FEDGAS was found to be approximately 20-fold higher than in FaSSIF-V2 and approximately 7-fold higher than in FeSSIF-V2. The results are shown in Figure 13.

Claims

1. Crystalline mesylate salt of linaprazanglerate.

2. 2. The crystalline mesylate salt of linaprazanglerate of claim 1, wherein the crystalline mesylate salt is stable at room temperature and 94% relative humidity.

3. The crystalline mesylate salt of linaprazanglerate of claim 1 or 2, which is a non-stoichiometric hydrate.

4. 4. The crystalline mesylate salt of linaprazanglerate of claim 3, which is form A having an XRPD pattern obtained using CuKα1 radiation having at least two peaks at 2θ values ​​(°) selected from the list consisting of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.

2.

5. 5. The crystalline mesylate salt of linaprazanglerate of claim 4, wherein form A has an XRPD pattern obtained using CuKα1 radiation having at least peaks at 2θ values ​​(°) of 7.5±0.2, 9.1±0.2, 16.0±0.2, and 17.6±0.

2.

6. 5. The crystalline mesylate salt of linaprazanglerate of claim 4, wherein form A has an XRPD pattern obtained using CuKα1 radiation having at least peaks at 2θ values ​​(°) of 7.5±0.2, 9.1±0.2, 12.1±0.2, 16.0±0.2, 17.6±0.2, 21.9, 24.3±0.2, 24.6±0.2, and 25.3±0.

2.

7. 4. The crystalline mesylate salt of linaprazanglerate of claim 3, which is Form A having an XRPD pattern obtained using CuKα radiation substantially as shown in FIG. 1 or FIG.

2.

8. 8. The crystalline mesylate salt of linaprazanglerate of any one of claims 4 to 7, wherein form A has a DSC curve that includes an endotherm between about 175°C and about 200°C.

9. 4. The crystalline mesylate salt of linaprazanglerate of claim 3, which is form B having an XRPD pattern obtained using CuKα1 radiation having at least two peaks at 2θ values ​​(°) selected from the list consisting of 6.4±0.2, 7.0±0.2, 9.4±0.2, 14.6±0.2, 15.6±0.2, 18.2±0.2, 21.8±0.2, 23.4±0.2, 24.4±0.2, and 25.4±0.

2.

10. 10. The crystalline mesylate salt of linaprazanglerate of claim 9, wherein form B has an XRPD pattern obtained using CuKα1 radiation having at least peaks at 2θ values ​​(°) of 6.4±0.2, 7.0±0.2, 9.4±0.2, and 15.6±0.

2.

11. 10. The crystalline mesylate salt of linaprazanglerate of claim 9, wherein form B has an XRPD pattern obtained using CuKα1 radiation having at least peaks at 2θ values ​​(°) of 6.4±0.2, 7.0±0.2, 9.4±0.2, 15.6±0.2, 18.2±0.2, 23.4±0.2, and 25.4±0.

2.

12. 4. The crystalline mesylate salt of linaprazanglerate of claim 3, which is form B having an XRPD pattern obtained using CuKα radiation substantially as shown in FIG.

13. 13. The crystalline mesylate salt of linaprazanglerate of any one of claims 9 to 12, wherein form B has a DSC curve comprising an endotherm between about 100°C and about 130°C.

14. 14. The crystalline mesylate salt of linapraganc of any one of claims 1 to 13, having a crystallinity of greater than 99%.

15. 15. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline mesylate salt of linapraganc of any one of claims 1 to 14 in combination with one or more pharma- ceutically acceptable excipients.

16. 15. The crystalline mesylate salt of linapraganc according to any one of claims 1 to 14, for use in therapy.

17. 15. The crystalline mesylate salt of linapraganc as claimed in any one of claims 1 to 14 for use in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases.

18. The crystalline mesylate salt of linaprazanurate for use according to claim 17, wherein the gastrointestinal inflammatory disease or gastric acid related disease is gastritis, gastroesophageal reflux disease (GERD), erosive gastroesophageal reflux disease (eGERD), H. pylori infection, Zollinger-Ellison syndrome, peptic ulcer disease (including gastric ulcer and duodenal ulcer), bleeding gastric ulcer, symptoms of gastroesophageal reflux disease (including heartburn, regurgitation and nausea), gastrinoma, or acute upper gastrointestinal bleeding.

19. The crystalline mesylate salt of linaprazanurate for use according to claim 17, wherein the gastrointestinal inflammatory disease or gastric acid related disease is erosive gastroesophageal reflux disease (eGERD).

Citation Information

Patent Citations

  • Solid 5-(2-(8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridine-6-formamido)ethoxy)-5-oxovaleric acid and preparation method thereof

    CN106279151A

  • Imidazopyridine derivatives that suppress gastric acid secretion

    JP2012510505A

  • CN10627915

  • Imidazo pyridine derivatives which inhibit gastric acid secretion

    WO1999055706A1

  • Imidazopyridine derivatives which inhibit the secretion of gastric acid

    WO2010063876A1